Last reviewed · How we verify
Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function After Early Intensive Diabetes Treatment
All subjects will be randomized as Alo/Pio combo group (intervention) or Glim/Met combo group (control) after intensive COAD treatment based on identical protocol. * All subject will be managed with once daily, fixed dose, single tablet treatment based on the study protocol, and followed-up for 104 weeks. * Any group of subjects who fail to reach glycemic target with single tablet treatment, subject will be treated with rescue medication and stopped regular observation.
Details
| Lead sponsor | Kyunghee University Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 96 |
| Start date | 2017-07 |
| Completion | 2021-12 |
Conditions
- Diabetes
Interventions
- NESINA ACT TAB. 25/15mg
- AMARYL-M TAB. 2/500mg
Primary outcomes
- Cumulative treatment failure (HbA1c≥7.0%) rate for glycemic control — 104 weeks from randomization
Countries
South Korea